Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
2269 | Hong Kong | HKD | Delayed | |
WXIBF | OTC Markets | USD | Delayed |
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh. It also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, production and sales of medicals, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and engages in investment and material supplier activities. The company has a research service agreement with BioNTech SE to discover and investigate monoclonal antibodies for developing next-generation therapeutic product candidates. The company was incorporated in 2014 and is headquartered in Wuxi, China.
Name | Age | Since | Title |
---|---|---|---|
Ge Li | 56 | 2014 | Founder & Chairman |
Zhisheng Chen | 50 | 2014 | CEO & Executive Director |
Jue Chen | 53 | 2023 | Independent Non-Executive Director |
Weichang Zhou | 60 | 2015 | Honorary President of Global Biologics Development, Senior Advisor to CEO & Non-Executive Director |
Kenneth Walton Hitchner | 63 | 2020 | Independent Non-Executive Director |
Yibing Wu | 56 | 2016 | Non-Executive Director |
Yanling Cao | 40 | 2016 | Non-Executive Director |
William Robert Keller | 76 | 2017 | Independent Non-Executive Director |
James W. Larrick | - | 2018 | Member of Scientific Advisory Board |
Wei-Shou Hu | - | 2018 | Member of Scientific Advisory Board |
Jackson Peter Tai | 74 | 2023 | Independent Non-Executive Director |
Ram Sasisekharan | 59 | 2018 | Member of Scientific Advisory Board |
David D. Ho | 71 | 2018 | Member of Scientific Advisory Board |
Rolf G. Werner | - | 2023 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review